Boehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines.
Austria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on its AI-enabled platform.
Swedish life science company PeptiSystems has appointed Ida Nordberg as Chief Financial Officer (CFO). The appointment marks another milestone in the company’s development and further strengthens the organization as it enters its next phase of commercialization and international expansion
French gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing.
https://european-biotechnology.com/wp-content/uploads/2026/07/vasilis-caravitis-lWa-7sY-CJI-unsplash-scaled.jpg19202560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-07 07:30:062026-07-06 17:49:49EG 427 rebrands as Cyllene and cashes in €33m Series C
Biotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and deep disease expertise into drugs more likely to work in patients.
https://european-biotechnology.com/wp-content/uploads/2025/11/Peter-Hamley-CEO-Scripta-Theraputics.png9001200Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-06 11:32:462026-07-07 15:33:30Where will AI actually move the needle in drug discovery?
Novartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours.
https://european-biotechnology.com/wp-content/uploads/2026/07/novartis-logo-banting-1-vertical-scaled.jpg20572560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-06 10:20:032026-07-06 10:20:03Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal
Roche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast cancer drug Kisqali.
https://european-biotechnology.com/wp-content/uploads/2026/07/angiola-harry-SJCalEw-1LM-unsplash-scaled.jpg17022560Richard Staines/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngRichard Staines2026-07-06 09:10:002026-07-06 13:10:04Genentech signs $490m breast cancer deal with Astex
SLAS Europe 2026 in Vienna brought together over 1,500 delegates for three days of innovation and collaboration. As we look ahead, join us at upcoming Meet-Ups in Leiden and Tübingen, and mark your calendars for SLAS2027 in San Diego, California.
https://european-biotechnology.com/wp-content/uploads/2026/06/Seite-55_ebm226-asso-slasslasEU_day1_highlights-16.jpg540960Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-06 08:00:192026-06-29 08:29:55SLAS Europe 2026 – Recap and Outlook
With the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
https://european-biotechnology.com/wp-content/uploads/2026/07/EB.com_Russell-thomas.jpg772687Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-03 13:24:382026-07-03 13:24:38One CSO for two companies
AstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases.
Boehringer licenses PVT virus platform for cancer vaccines
Latest NewsBoehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines.
Graph Therapeutics raises $5m to advance I&I pipeline
Latest NewsAustria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on its AI-enabled platform.
New CFO to Drive Commercial Growth
AppointmentsSwedish life science company PeptiSystems has appointed Ida Nordberg as Chief Financial Officer (CFO). The appointment marks another milestone in the company’s development and further strengthens the organization as it enters its next phase of commercialization and international expansion
EG 427 rebrands as Cyllene and cashes in €33m Series C
Latest NewsFrench gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing.
Where will AI actually move the needle in drug discovery?
Latest News, OpinionBiotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and deep disease expertise into drugs more likely to work in patients.
Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal
Latest NewsNovartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours.
Genentech signs $490m breast cancer deal with Astex
Latest NewsRoche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast cancer drug Kisqali.
SLAS Europe 2026 – Recap and Outlook
AssociationsSLAS Europe 2026 in Vienna brought together over 1,500 delegates for three days of innovation and collaboration. As we look ahead, join us at upcoming Meet-Ups in Leiden and Tübingen, and mark your calendars for SLAS2027 in San Diego, California.
One CSO for two companies
AppointmentsWith the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
AstraZeneca returns to CSPC with $1.77bn kidney deal
Latest NewsAstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases.